Drug Search Results
Using advanced filters...
Advanced Search [+]

Sodium chloride

Alternative Names: sodium chloride, sodium-chloride, sodium chloride 0.9% in plastic container, sodio cloruro, natriumklorid, natriumchlorid, natrijev klorid, natrii chloridi infundibile, cloruro de sodio, cloreto de sodio, broncho saline, diluent, nacellate solution 0.9% - 500ml, nacellate solution 0.9% - 100ml, nacellate solution 0.9% - 250ml, hespan, nacellate solution 0.9% - 1000ml, corvatrol 0.9%, moviprep, plenvu, golytely, nulytely, balanced salt, tis-u-sol, procalamine, colyte with flavor packs, aminosyn ii 8.5% w/ electrolytes, colyte-flavored, glycoprep, go-evac, aminosyn 3.5% m in plastic container, isolyte s ph 7.4 in plastic container, lactated ringer's in plastic container, plasma-lyte 56 in plastic container, isolyte e in plastic container, prismasol bgk 4/0 in plastic container, ringer's in plastic container, prismasol b22gk 2/0 in plastic container, aminosyn 8.5% w/electrolytes, aminosyn ii 3.5% m in plastic container, isolyte s in plastic container, phoxillum b22k 4/0 in plastic container, prismasol bk 0/3.5 in plastic container, prismasol bgk 4/2.5 in plastic container, travasol 5.5% sulfite free w/ electrolytes in plastic container, plasma-lyte r in plastic container, prismasol bgk 4/3.5 in plastic container, travasol 3.5% sulfite free w/ electrolytes in plastic container, colyte, bss, physiolyte in plastic container, normosol-r in plastic container, e-z-em prep lyte, prismasol b22gk 4/2.5 in plastic container, tis-u-sol in plastic container, aminosyn 7% w/ electrolytes, aminosyn ii 7% w/ electrolytes, physiosol ph 7.4 in plastic container, plegisol in plastic container, multiple electrolytes injection type 1 usp ph 5.5, plasma-lyte 148 in water in plastic container, prismasol bgk 2/0 in plastic container, trilyte, nulytely-flavored, normocarb hf 35, aminosyn 3.5% m, aminosyn ii 10% w/ electrolytes, lax-lyte with flavor packs, prismasol bk 0/0/1.2 in plastic container, tpn electrolytes in plastic container, prismasol bk 0/0 in plastic container, prismasol b22gk 2/2.5 in plastic container, tham-e, travasol 3.5% w/ electrolytes, travasol 8.5% sulfite free w/ electrolytes in plastic container, clenz-lyte, peg-lyte, colovage, prismasol b22gk 4/0 in plastic container, aminosyn ii 3.5% m, freamine iii 3% w/ electrolytes, co-lav, acetated ringer's in plastic container, aminosyn 8.5% w/ electrolytes, aminosyn ii 8.5% w/electrolytes, travasol 8.5% w/ electrolytes, multiple electrolytes injection type 1 usp ph 7.4, bss plus, physiosol in plastic container, prismasol bgk 2/3.5 in plastic container, phoxillum bk 4/2.5 in plastic container, elliotts b solution, cardioplegic in plastic container, prismasol bk 4/2.5 in plastic container, travasol 5.5% w/ electrolytes, synovalyte in plastic container, ocl, plasma-lyte a in plastic container, prismasol bgk 4/0/1.2 in plastic container, navstel, prismasol bgk 0/2.5 in plastic container, normocarb hf 25, suclear
Latest Update: 2025-05-15
Latest Update Note: News Article

Product Description

Sodium chloride is an inorganic chloride salt having sodium(1+) as the counterion. It has a role as an emetic and a flame retardant. It is an inorganic chloride and an inorganic sodium salt. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Sodium-chloride)

Mechanisms of Action: No Mechanism

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous,Intramuscular,Subcutaneous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Norgine
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Sodium chloride

Countries in Clinic: Australia, Austria, Belgium, Brazil, Bulgaria, Chile, China, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, India, Ireland, Italy, Japan, Kenya, Latvia, Lithuania, Malawi, Mexico, Netherlands, Norway, Peru, Philippines, Poland, Portugal, Russia, Slovenia, South Africa, South Korea, Spain, Sweden, Taiwan, Thailand, Uganda, United Kingdom, United States, Unknown Location, Zimbabwe

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Abscess|Asthma, Allergic|Ataxia Telangiectasia|Cervical Cancer|Cervical Intraepithelial Neoplasia|Communicable Diseases|Conjunctivitis, Allergic|Dust mite Hypersensitivity|Emphysema|Endometritis|Environmental Hypersensitivity|Esophageal Cancer|HIV Infections|Heart Failure|Inflammation|Influenza, Human|Injuries/wounds Unspecified|Kidney Diseases|Lyme Disease|Meningitis|Non-Small-Cell Lung Cancer|Oophoritis|Ovarian Diseases|Papillomavirus Infections|Peritonitis|Pleural Effusion, Malignant|Pneumonia|Rhinitis, Allergic|Salpingitis|Small Cell Lung Cancer|Squamous Intraepithelial Lesions of the Cervix|Thyroid Eye Disease|Urinary Tract Infections|alpha 1-Antitrypsin Deficiency

Phase 2: Abdominal Pain|Acute Coronary Syndrome|Alzheimer Disease|Anesthesia Related|Atrial Fibrillation|Bronchopulmonary Dysplasia|CADASIL|COVID-19|Cardiac Arrest|Chickenpox|Chronic Pain|Fatty Liver, Alcoholic|Glabellar Reflex|Gonorrhea|Hepatitis E|Herpes Zoster|Hypotension, Orthostatic|Ischemic Stroke|Keratoconjunctivitis Sicca|Low Back Pain|Lymphoma|Neuromyelitis Optica|Non-alcoholic Fatty Liver Disease|Orthostatic Intolerance|Osteoarthritis, Knee|Pseudomonas Infections|Sexually Transmitted Diseases|Staphylococcal Infections|Surgical Wound Infection|Total Knee Arthroplasty|beta-Thalassemia

Phase 1: Acute Pain|Adenoviridae Infections|Angina Pectoris|Appendicitis|Arthritis, Infectious|Arthritis, Rheumatoid|Bacteroides Infections|Bronchiectasis|Clostridium Infections|Conjunctivitis|Coronary Disease|Gram-Positive Bacterial Infections|Healthy Volunteers|Hypertension|Keratitis|Myocardial Infarction|Other|Pelvic Infection|Pelvic Inflammatory Disease|Pneumococcal Infections|Pyelonephritis|Respiratory Syncytial Virus Infections|Spinal Diseases|Type 2 Diabetes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

SRB2021260

P2

Recruiting

Cardiac Arrest

2030-11-30

VAC52416BAC3001

P3

Active, not recruiting

Urinary Tract Infections

2029-06-30

90%

EVENEW

P2

Recruiting

Bronchopulmonary Dysplasia

2028-06-30

CN008-0003

P2

Active, not recruiting

Alzheimer Disease

2027-11-16

12%

RG1123550

P2

Recruiting

Lymphoma

2027-07-31

83%

2024-514903-33-00

P2

Active, not recruiting

Total Knee Arthroplasty|Osteoarthritis, Knee

2027-06-01

CQ-001-19

P3

Recruiting

Heart Failure

2027-04-01

MOZEG

P2

Not yet recruiting

Ischemic Stroke

2027-03-03

MK-3475-091

P3

Active, not recruiting

Small Cell Lung Cancer|Non-Small-Cell Lung Cancer

2027-02-02

FTP-CLIN-01

P2

Recruiting

Glabellar Reflex

2026-01-27

GLORIA - PP-SA-003

P2

Not yet recruiting

Unknown

2026-12-01

12%

SC-3C2A

P3

Active, not recruiting

Conjunctivitis, Allergic|Rhinitis, Allergic|Asthma, Allergic

2026-09-30

PM/0059

P3

Active, not recruiting

Rhinitis, Allergic|Asthma, Allergic|Environmental Hypersensitivity|Dust mite Hypersensitivity|Conjunctivitis, Allergic

2026-08-31

GTi1201

P3

Active, not recruiting

Emphysema|alpha 1-Antitrypsin Deficiency

2026-08-12

FGTW2101

P3

Recruiting

Injuries/wounds Unspecified

2026-04-30

API-EAD-2024-01

P2

Withdrawn

Unknown

2026-03-31

2024-513828-42-00

P2

Recruiting

CADASIL

2026-03-31

STOOD

P2

Recruiting

Orthostatic Intolerance|Hypotension, Orthostatic

2026-03-01

RNCVCT7B001

P1

Enrolling by invitation

Communicable Diseases|Pneumococcal Infections

2026-02-01

12%

IVI Hecolin S001

P2

Not yet recruiting

Hepatitis E

2026-01-01

C4601003

P3

Active, not recruiting

Lyme Disease

2025-12-31

43%

DUO2022_01

P2

Not yet recruiting

Surgical Wound Infection

2025-12-31

DUO2022_01

P2

Recruiting

Surgical Wound Infection|Communicable Diseases|Pseudomonas Infections|Staphylococcal Infections

2025-12-31

12%

218672

P2

Active, not recruiting

Fatty Liver, Alcoholic|Non-alcoholic Fatty Liver Disease

2025-12-15

12%

NVL-2024-257

P2

Not yet recruiting

Osteoarthritis, Knee

2025-09-13

50%

Recent News Events